ERS statement on Philips devices: clinicians’ and patients’ perspectives, and questions to be answered

Philips Respironics has recently released a Field Safety Notification for a number of positive airway pressure (PAP) devices used for treatment of sleep apnoea and respiratory failure. According to the manufacturer, the polyester-based polyurethane foam used in their devices may degrade into particles and volatile gas products, which the user may inhale. This may result in potential health risks for the user, including local airway irritation.

This webinar offers the opportunity to assess the real and potential acute and chronic risk for the patient due to physical or chemical injuries on the one hand, against the acute and chronic risk of cessation of treatment of sleep apnoea or respiratory failure on the other, and discusses the current realised recommendations for respiratory, sleep and critical care medicine professionals and patients regarding the Phillips recall notice.